In solid tumors, antibody-mediated inhibition of CALCRL signaling has been shown to reduce tumor growth [16–18] and it is currently being examined as a new and promising candidate therapeutic target for AML [8, 9]. This evidence concerns the gene CALCRL and acute myeloid leukemia.